Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

ConclusionEptinezumab 100 mg or 300 mg administered IV at day 0 and repeated at week 12 provided sustained migraine preventive benefit over a full 24 weeks and demonstrated an acceptable safety profile in patients with chronic migraine.Trial registrationClinicalTrials.gov (Identifier:NCT02974153). Registered November 23, 2016.

http://link.springer.com/10.1186/s10194-020-01186-3

Source: The Journal of Headache and Pain - October 5, 2020 Category: Neurology Source Type: research